Technicals — Down 23.9% to $64.27 on 8.3x volume — the worst session since March 2021 — one candle slicing through every moving average (the 20-, 50- and 200-day all cluster near $76). RSI at 31.1 approaches oversold without being extreme, and the $75–78 gap won't fill anytime soon.
Fundamentals — The AstraZeneca-partnered Phase 3 CARDIO-TTRansform trial of eplontersen (Wainua) in ATTR cardiomyopathy missed its primary endpoint — no statistically significant reduction in CV death and recurrent events through week 140 versus placebo. ATTR-CM is a multi-billion-dollar market, and that growth curve just got erased; the approved polyneuropathy indication and the rest of the pipeline stand, but the valuation lost a pillar.
News — Jefferies and BofA both cut targets to $90 (from $113 and $111, Buys intact) the same day, and law firms have launched investigation notices. Yet StockTwits retail is euphoric — 'opportunity of a lifetime' trended. A day of institutions cutting targets while retail yells bottom.
Day one of a pipeline-failure crash is never the bottom: index rebalancing, risk-desk liquidations and target cuts roll on for days. 8.3x volume says the hand-off has only started.
The antisense platform remains a scarce technology asset with an approved-product floor; but filling the ATTR-CM hole needs new pipeline data, and rebuilding trust takes time.
- AstraZeneca dialing back commercial investment
- Law-firm investigations and potential class actions
- A dense readout calendar keeps volatility elevated
- StockTwits · 'Opportunity of a lifetime' — the board chants it every time a pipeline blows up; the one right call gets remembered, the nine wrong ones never come upOriginal ↗
